Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137510 | 1.00 | KCNH2 (0.43) | KCNH2SSTR5SLC2A1CLK1 | |
| SCHEMBL2254016 | 1.00 | KCNH2 (0.43) | KCNH2SSTR5SLC2A1CLK1 | |
| SCHEMBL2250560 | 1.00 | KCNH2 (0.43) | KCNH2SSTR5SLC2A1CLK1 | |
| SCHEMBL2256847 | 0.88 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL2252556 | 0.88 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL2252560 | 0.88 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL2253508 | 0.83 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL2255530 | 0.83 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL2253511 | 0.83 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL3154178 | 0.82 | KCNH2 (0.35) | KCNH2SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999115-B2 | Spiro antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (SE) | 2011-08-16 | — | — | US | claimed |
| EP-2066678-B1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-10 | — | — | EP | claimed |
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | claimed |
| EP-2066678-A1 | SPIRO ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-10 | — | — | EP | claimed |
| WO-2008026172-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | claimed |
| US-7999115-B2 | Spiro antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (SE) | 2011-08-16 | — | — | US | disclosed |
| EP-2066678-B1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-10 | — | — | EP | disclosed |
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-2066678-A1 | SPIRO ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008026172-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | NR0B1, NRDC, NR4A1 | KCNH2 1177/4885SSTR5 1949/4885SLC2A1 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.